EGFR-IN-203 is a EGFR kinase domain inhibitor targeting EGFRT790M/C797S/V948R. EGFR-IN-203 stably binds to the allosteric pocket of EGFR in an inactive conformation. EGFR-IN-203 can be used in research related to cancers such as non-small cell lung cancer.

EGFR-IN-202 is an epidermal growth factor receptor (EGFR) inhibitor that selectively targets EGFR exon 20 insertion mutations. EGFR-IN-202 can be used in research related to non-small cell lung cancer.

EGFR-IN-199 is a selective and potent EGFR inhibitor with IC50 values of 1.1 nM and 1.4 nM for purified EGFR WT and EGFRT790M/L858R kinases. EGFR-IN-199 can be used for the research of cancer.

EGFR-IN-197 is an EGFR inhibitor with IC50 values of 19.5 nM and 12.0 nM against EGFRL858R/T790M and EGFRL858R/T790M/C797S, respectively. EGFR-IN-197 arrests the cell cycle of NCI-H1975 cells at the G2/M phase, while inhibiting their proliferation, colony formation and migration; it also inhibits mitochondrial translocation and upregulates mitochondrial H2S levels. EGFR-IN-197 disrupts anti-apoptotic signaling pathways by regulating apoptosis-related proteins; it induces DNA damage and activates pro-apoptotic pathways to trigger apoptosis. EGFR-IN-197 can be used in studies related to non-small cell lung cancer (NSCLC).

EGFR-IN-193 is an EGFR inhibitor, which can be used to synthesize PROTACs as target protein ligands, such as PROTAC EGFR degrader 17.

EGFR-IN-189 (Compound 7) is a selective covalent epidermal growth factor receptor (EGFR) inhibitor with an IC50 of 200 nM. EGFR-IN-189 can effectively inhibit the C797S mutant type of EGFR. EGFR-IN-189 can inhibit cancer cells proliferation and inhibit EGFR phosphorylation and downstream ERK1/2 phosphorylation. EGFR-IN-189 can be used for research of nonsmall cell lung cancer.

EGFR-IN-179 (Compound 8d) is an EGFR inhibitor (IC50: 0.068 μM for EGFR L858R/T790M/C797S; 2.56 μM for EGFR-WT-TK). EGFR-IN-179 has anticancer activity against non-small cell lung cancer.

EGFR-IN-177 is a potent EGFR inhibitor with IC50s of 0.32, 1.04, 0.65, 0.67, 0.48, 0.55 and 0.38 nM against EGFR L858R, EGFR L858R/T790M, EGFR L858R/T790M/C797S, EGFR D746-750, EGFR D746-750/C797S, EGFR D770_N77linsNPG, and EGFR WT. EGFR-IN-177 inhibits lung cancer proliferation and EGFR phosphorylation. EGFR-IN-177 can be used for the study of cancers such as non-small cell lung cancer.

EGFR/VEGFR2-IN-11 is an EGFR/VEGFR2 inhibitor with IC50 values of 0.62 μM (human EGFR), 2.26 μM (human VEGFR-2), 17.38 μM (human COX-2), and 19.31 μM (human tubulin). EGFR/VEGFR2-IN-11 inhibits COX-2 activity and tubulin polymerization. EGFR/VEGFR2-IN-11 induces cell cycle arrest and apoptosis. EGFR/VEGFR2-IN-11 exerts selective and antiproliferative activity against human cancer cells. EGFR/VEGFR2-IN-11 can be used for the research of colon carcinoma, breast carcinoma, leukemia, lymphoma, glioblastoma.

EGFR kinase-IN-8 (Compound H8b) is an EGFR inhibitor. EGFR kinase-IN-8 potently inhibits both triple-mutated EGFRL858R/T790M/C797S (IC50 = 3.86 nM) and double-mutated EGFRL858R/T790M (IC50 = 1.23 nM). EGFR kinase-IN-8 suppresses EGFR phosphorylation and downstream AKT, STAT3, and MAPK signaling. EGFR kinase-IN-8 exhibits anticancer activity against non-small cell lung cancer.

EDP-420 (EP-013420; S-013420) is an orally active antibacterial agent. EDP-420 inhibits the Mycobacterium avium complex (MAC) in macrophages. EDP-420 reduces bacterial counts in a mouse model of macrolide infection. EDP-420 inhibits pneumococcal activity in a rabbit model of meningitis. EDP-420 can be used in research on inflammatory infectious diseases such as meningitis.

Echinocandin B (purity>65%) (SL 7810 (purity>65%)) is a lipopeptide antifungal antibiotic. Echinocandin B (purity>65%) is produced by Aspergillus nidulans. Echinocandin B (purity>65%) inhibits β-1,3-glucan activity, thereby blocking the biosynthesis of fungal cell walls. Echinocandin B (purity>65%) exhibits activity against a variety of Aspergillus species.

EC0652 is a PSMA imaging agent with SPECT imaging capability. EC0652 can be used for the research of metastatic castration-resistant prostate cancer.

E-6837 is a selective and orally active 5-HT6 receptor ligand. E-6837 demonstrates partial agonism at a presumably silent rat 5-HT6 receptor and full agonism at a constitutively active human 5-HT6 receptor by monitoring the cAMP signaling pathway. E-6837 induces hypophagia, reduces fat mass and body weight, and improves glycemic control. E-6837 can be used for the research of obesity.

E3 Ligase Ligand-linker Conjugate 226 is a synthetic E3 ligase ligand-linker conjugate that can be used to synthesize PROTACs, such as PROTAC IRAK3 degrader-2. GXF-111 is a IRAK PROTAC degrader with anti-tumor activity.

E3 Ligase Ligand-linker Conjugate 224 is an E3 Ligase Ligand-Linker Conjugate that incorporates a ligand for VHL and a PROTAC linker. E3 Ligase Ligand-linker Conjugate 224 can be used for synthesis of KRAS G12D PROTAC degrader MS243.

E3 Ligase Ligand-linker Conjugate 214 is an E3 ligase ligand-linker conjugate containing a Von Hippel-Lindau (VHL) ligand and a linker. E3 Ligase Ligand-linker Conjugate 214 can bind to a target protein ligand to form a PROTAC molecule, PROTAC LSD1 Degrader 1.

E2072 is a selective, orally active competitive inhibitor of glutamate carboxypeptidase II (GCPII) with a Ki of 10 nM. E2072 alleviates established thermal hyperalgesia in a rat model of chronic constriction injury. E2072 prevents oxaliplatin-induced reductions in nerve conduction velocity and amplitude in mice. E2072 is applicable to research related to neuropathic pain and neuropathy.

E12LA6B6O3 is an amino lipid that can be used to prepare nanoparticles for drug delivery, such as mRNA.

DZX19 (Compound C02) is an orally active, selective TRK inhibitor with a TRKA IC50 value of 1.32 nM, a TRKB IC50 of 2.28 nM, and a TRKC IC50 of 4.05 nM. DZX19 inhibits the kinase activities of wild-type TRKA, TRKA mutants (G595R, F589L, G667C), wild-type TRKB, and wild-type TRKC, and suppresses the phosphorylation of TRKA as well as its downstream AKT and ERK signaling pathways. DZX19 induces apoptosis. DZX19 inhibits tumor growth in a colorectal cancer xenograft mouse model. DZX19 is applicable for the research of colorectal cancer.

Dyrk1A-IN-17 is an orally active and blood-brain barrier-permeable multi-kinase inhibitor. Dyrk1A-IN-17 reduces the excessive phosphorylation of α-synuclein by inhibiting four kinases (ABL1, DYRK1A, GSK3β, and LRRK2) and stabilizing microtubules. Dyrk1A-IN-17 is applicable for research on neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease.

Dyrk1A-IN-16 is a selective, brain-penetrant and ATP-competitive Dyrk1A inhibitor with a IC50 of 53 nM. Dyrk1A-IN-16 displays high selectivity across a broad kinase panel (specific for DYRK kinases) with nanomolar potency. Dyrk1A-IN-16 impairs neurosphere self-renewal, cell invasion, and EGFR stability in vitro. Dyrk1A-IN-16 inhibits tumor growth and prolongs survival in vivo. Dyrk1A-IN-16 has potential for glioblastoma (GBM) research.

Dyrk1A-IN-15 is a selective, brain-penetrant and ATP-competitive Dyrk1A inhibitor with a IC50 of 19 nM. Dyrk1A-IN-15 displays high selectivity across a broad kinase panel (specific for DYRK kinases) with nanomolar potency. Dyrk1A-IN-15 impairs neurosphere self-renewal, cell invasion, and EGFR stability in vitro. Dyrk1A-IN-15 inhibits tumor growth and prolongs survival in vivo. Dyrk1A-IN-15 has potential for glioblastoma (GBM) research.

DY-9760e is a calmodulin (CaM) inhibitor. DY-9760e selectively inhibits the activity of various calmodulin-dependent enzymes by antagonizing the Ca²⁺/CaM complex, exhibiting the strongest inhibitory activity against nNOS, CaM kinase II, and calcineurin (Ki: 0.9, 1.4, and 2.0 μM, respectively). DY-9760e inhibits excessive nitric oxide production and protein tyrosine nitration, as well as the activation of calpain and caspase-3. DY-9760e reduces infarct size, improves cardiac function, and inhibits oxidative stress and cell death. DY-9760e can be used in research on the treatment of myocardial infarction, cerebral ischemia, and other diseases.

DX-8951 Hydroxy-acid is a prodrug of phosphoramide. ProAX can effectively increase intracellular ATP levels. DX-8951 Hydroxy-acid activates the AMPK signaling pathway by increasing the AMP/ATP ratio. DX-8951 Hydroxy-acid can enhance mitochondrial function and antioxidant capacity while reducing reactive oxygen species (ROS) levels. DX-8951 Hydroxy-acid has shown significant anti-aging and longevity effects in both human fibroblast and nematode models.

Dupracetam is a Piracetam analog. Dupracetam antagonizes the lethality of HC-3.

DTPA-adenosylcobalamin is an Adenosylcobalamin and Pentetic acid conjugate. DTPA-adenosylcobalamin can used as a radioactive probe for diagnosing the absorption of vitamin B12 in tumor.

DSA8 is a type II kinase inhibitor with IRE1 RNase modulating activity. DSA8 can be used for the research of cancer, metabolic disease, suah as diabetes.

DRP1 Allosteric-IN-3 (Compound 2b) is an allosteric inhibitor of DRP1. Its IC50 value for the DRP1:MiD49 protein-protein interaction is 11 μM. DRP1 Allosteric-IN-3 can be used to study various diseases related to mitochondrial division disorders.

Droxinavir (SC-55389A) free base is an HIV-1 protease inhibitor and antiviral agent. Droxinavir binds to the S2 and S2' subsites of HIV-1 protease, and this interaction is regulated by protease amino acid residue 88, where the N88S mutation confers viral resistance. Droxinavir can be used in studies related to human immunodeficiency virus type 1 infection.